Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028535 · ClinicalTrials.gov registry record · Phase 1
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
A Phase 1 study of Recurrent Endometrial Carcinoma and Recurrent Breast Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00028535 is a Phase 1 study of Recurrent Endometrial Carcinoma and Recurrent Breast Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants, below the 252-participant average among 19 other Recurrent Endometrial Carcinoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00028535, a Phase 1 study of Recurrent Endometrial Carcinoma and Recurrent Breast Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of interleukin-12, paclitaxel, and trastuzumab in treating patients who have solid tumors. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining interleukin-12, chemotherapy, and monoclonal antibody therapy may kill more tumor cells.
Conditions Studied
Interventions
- DRUG paclitaxel
- BIOLOGICAL trastuzumab
- BIOLOGICAL recombinant interleukin-12
Study Locations (1)
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2001-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028535
The ClinicalTrials.gov registry entry for NCT00028535 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 252-participant average among 19 other Recurrent Endometrial Carcinoma trials with a reported enrollment target (93% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Recurrent Endometrial Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which paclitaxel is the first listed.
NCT00028535 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00028535 about?
NCT00028535 is a clinical study titled "Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors". Phase I trial to study the effectiveness of interleukin-12, paclitaxel, and trastuzumab in treating patients who have solid tumors. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Drugs used in chemotherapy...
What is the current status of trial NCT00028535?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2001-11.
What conditions does trial NCT00028535 study?
This clinical trial studies the following conditions: Recurrent Endometrial Carcinoma, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Male Breast Cancer, Recurrent Ovarian Epithelial Cancer.
What interventions are being tested in trial NCT00028535?
The interventions under investigation include: paclitaxel (DRUG), trastuzumab (BIOLOGICAL), recombinant interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00028535?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00028535 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Endometrial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
RECRUITING · Phase 1
-
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
RECRUITING · Phase 1
-
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
RECRUITING · Phase 1
-
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
RECRUITING · Phase 1
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
-
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.